Non-Alcoholic Steatohepatitis Treatment Market Outlook Highlighting Key Drivers And Market Evolution
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Will The Market Value Of The Non-Alcoholic Steatohepatitis Treatment Market Progress Between 2026 And 2030?
The non-alcoholic steatohepatitis treatment market has seen rapid expansion in its size over recent years. It is anticipated to expand from $3.57 billion in 2025 to $4.98 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 39.6%. Factors contributing to this historical expansion include the escalating prevalence of obesity, a surge in the incidence of type 2 diabetes, considerable intake of processed foods, insufficient understanding of liver health, and constrained therapeutic choices for early-stage nash.
The non-alcoholic steatohepatitis treatment market is projected to experience rapid expansion over the coming years. This market is forecast to reach $18.97 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 39.7%. Factors contributing to this growth during the outlook period include progress in precision medicine, the creation of innovative NASH drugs, the uptake of digital health monitoring instruments, governmental efforts aimed at preventing liver disease, and rising investment in liver disease research. Key trends anticipated for this forecast timeframe encompass individualized lifestyle and diet management, innovations in non-invasive diagnostics, initiatives for fatty liver disease awareness, at-home liver health monitoring, and the evolution of new pharmacological agents.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8595&type=smp
What Key Factors Are Shaping The Non-Alcoholic Steatohepatitis Treatment Market Landscape?
The non-alcoholic steatohepatitis treatment market is experiencing growth driven by a rising occurrence of insulin resistance. Insulin resistance manifests when the body’s muscle, fat, and liver cells fail to react sufficiently to insulin, impeding the effortless uptake of glucose from the bloodstream, which leads to elevated blood sugar levels. Factors such as an unhealthy lifestyle, excessive sugar intake, and genetic predispositions are associated with its development. The incidence of insulin resistance has expanded considerably, attributable to a rise in diabetes and various liver conditions, both of which are addressed by non-alcoholic steatohepatitis treatment. For example, in July 2025, PubMed, a free biomedical literature database based in the US and maintained by the U.S. National Library of Medicine, indicated a significant increase in the prevalence rates of general obesity, abdominal obesity, severe obesity, and insulin resistance, with these rates rising from 34.9% to 41.4%, 62.5% to 67.0%, 5.2% to 11.5%, and 22.5% to 30.2%, respectively. Consequently, the growing prevalence of insulin resistance, stemming from numerous liver and diabetes diseases, is set to propel the non-alcoholic steatohepatitis treatment market.
How Is The Non-Alcoholic Steatohepatitis Treatment Market Categorized Across Its Segment Groups?
The non-alcoholic steatohepatitis treatment market covered in this report is segmented –
1) By Drug Type: Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types
2) By Test Type: Blood Tests, Liver Biopsy, Imaging Procedures
3) By End User: Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users
Subsegments:
1) By Vitamin E And Pioglitazone: Vitamin E Supplements, Pioglitazone-Based Formulations.
2) By Ocaliva: Ocaliva (Obeticholic Acid) For NASH
3) By Elafibranor: Elafibranor Monotherapy, Elafibranor Combination Therapy
4) By Selonsertib And Cenicriviroc: Selonsertib Formulations, Cenicriviroc Formulations
5) By Obeticholic Acid: Immediate-Release Obeticholic Acid, Extended-Release Obeticholic Acid
6) By Other Drug Types: Novel Agents In Clinical Trials, Combination Therapies
What Market Trends Are Affecting The Non-Alcoholic Steatohepatitis Treatment Market?
Leading companies within the non-alcoholic steatohepatitis treatment market are actively developing innovative products, such as endogenous hormones, to cater to broader customer bases, boost sales, and increase revenue. Endogenous hormones are naturally occurring substances produced internally by various glands, tissues, or organs, playing vital roles in regulating physiological processes. For instance, in September 2023, 89bio Inc., a US-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) for Pegozafermin for individuals diagnosed with nonalcoholic steatohepatitis (NASH). Pegozafermin is distinct given it is an engineered glycoPEGylated analog of fibroblast growth factor 21. This specifically designed formulation is currently under development to address non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Pegozafermin’s uniqueness lies in its use of specialized glycoPEGylated technology, which ensures an extended half-life while maintaining its potency. This innovative approach enhances the product’s effectiveness in modulating key factors associated with lipid metabolism, NASH, and hypertriglyceridemia, including triglyceride reduction, glycemic control, steatosis, inflammation, and fibrosis.
Which Firms Are Influencing Competition In The Non-Alcoholic Steatohepatitis Treatment Market?
Major companies operating in the non-alcoholic steatohepatitis treatment market are AstraZeneca PLC, Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Novo Nordisk A/S, Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG
Get The Full Non-Alcoholic Steatohepatitis Treatment Market Report:
Which Region Represents The Largest Share Of The Non-Alcoholic Steatohepatitis Treatment Market?
North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2025. The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Non-Alcoholic Steatohepatitis Treatment Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Non-Alcoholic Steatohepatitis Treatment Market 2026, By The Business Research Company
Non Alcoholic Steatohepatitis Treatment Market Report 2026
Non Alcoholic Steatohepatitis Treatment Market Report 2026
Non Alcoholic Steatohepatitis Biomarkers Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
